Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced a new, proprietary diagnostic testing technique to help physicians diagnose genetic metabolic disorders, such as phenylketonuria (PKU) and homocystinuria. Genetic metabolic disorders can impair a child's mental and physical development. The new technique measures amino acids in blood plasma, urine or cerebral spinal fluid by employing a combination of liquid chromatography and mass spectrometry.
Physicians may also use amino acid quantitation tests on individuals whose ability to process nutrients may be impaired, such as those undergoing chemotherapy treatments for cancer, the elderly, and individuals with gastrointestinal illnesses.
0 comments :
Post a Comment